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The phenomenon of “diastolic heart failure” is rightly
receiving greater attention (1–4); community-based studies
such as those in Framingham (5) and Olmsted County (6)
show that up to 50% of older persons with heart failure do
not have impaired left ventricular (LV) systolic function to
account for this, and that the condition is usually associated
with LV hypertrophy and is preceded by elevation of systolic
blood pressure. Modern medicine has been slow to accept
diastolic dysfunction as a cause of heart failure, largely
because there are no accepted noninvasive measures of
diastolic dysfunction, there is a wide overlap in diastolic
function between persons with apparent diastolic heart
failure and the normal aged community, and the profession
has focused on impaired LV systolic function and coronary
atherosclerosis as the cause of myocardial scarring and
impaired LV contractility. Up until the year 2000 there had
been no randomized therapeutic studies of patients with
diastolic LV dysfunction. With a blank slide, Dr. W. Little
of Wake Forest University illustrated this to packed sessions
of the 49th and 50th American College of Cardiology
(ACC) meetings.
See page 796
In this issue of the Journal, Hundley et al. (7) draw
attention to the relationship between evidence of isolated
diastolic LV dysfunction and aortic stiffening, showing that
in older persons with diastolic heart failure, impaired
exercise tolerance correlates with aortic stiffening, and that
there is a highly significant difference between these patients
and a normal age-matched group. They also confirm that
there is a significant difference in exercise tolerance and
aortic stiffness between normal young persons ,30 years of
age and those over age 60. They argue that reduced aortic
distensibility (increased stiffness) is the likely cause of
diastolic dysfunction, reduced exercise tolerance and cardiac
failure.
This attention to aortic stiffness and cardiac dysfunction
may seem new, but it was the dominant focus in studies of
cardiovascular aging and arterial disease a century ago. The
English physiologist C.S. Roy in 1880 stated of humans
that “only in the case of young children do we find that the
elasticity of arteries is so perfectly adapted to the require-
ments of the organism as in the case of the lower animals”
(8). The Nobel Laureate A. V. Hill along with J. C.
Bramwell stated that “the amount of energy expended by
the heart . . . has been shown to be proportional to the
pressure developed . . . hence the amount of energy that the
heart has to expend per beat, other things being equal, varies
with the elasticity of the arterial system” (9). The same
investigators confirmed increase in arterial stiffness with age
from noninvasive measurement of pulse-wave velocity (10).
Queen Victoria’s physician, W. H. Broadbent, in 1875
described characteristic features of increased arterial tension
(from the radial pulse), of clinical LV hypertrophy (heaving
apex beat and fourth heart sound), exercise intolerance and
development of cardiac failure (11). The Senile Heart (12) by
G. W. Balfour in 1894 related symptoms of heart failure to
LV hypertrophy and stiffened arteries. The founder of
English cardiology, James Mackenzie, discussed developing
arteriosclerosis as causing impaired exercise capacity in the
fourth decade of life, and the progress of this to LV
hypertrophy and cardiac failure (13). Osler (14) described
arteriosclerosis as “nodular” (atherosclerosis), “diffuse” (hy-
pertensive) and “senile,” noting that the degenerations could
be mixed, but were progressive, and commonly culminated
in cardiac failure.
If this subject of arterial stiffening and cardiac failure is so
old, why has it been overlooked? Perhaps Peter Libby has
the answer when noting that practitioners of an era become
slaves to the technology of the era (15). By the late 20th
century, we had become preoccupied by the technologies
that define coronary artery narrowing and LV contractility.
The clinical era of sphygmography and pulse-wave analysis
in the early 20th century closed with the introduction of the
cuff sphygmomanometer. The cuff carried a mixed blessing.
Although it did provide noninvasive measures of systolic
and diastolic pressure, it also created preoccupation with
diastolic pressure as a measure of peripheral resistance, and
the view that diastolic pressure need be elevated for a
diagnosis of hypertension to be made and treatment initi-
ated. It is just one decade back that this concept was
overturned by the Systolic Hypertension in the Elderly
Program (SHEP) and other studies (16,17).
Sphygmomanometric studies of systolic pressure and
pulse pressure first drew modern attention to arterial stiff-
ness and its ill effects on the heart. The Framingham Study
showed marked increase in pulse pressure over age 50 (18),
whereas Framingham (19) and other studies (20,21) con-
sistently showed a positive relationship between pulse pres-
sure and cardiovascular events in persons over age 50 and
associated this with an increase in arterial stiffness. A neutral
(22) or inverse (23) relationship between pulse pressure and
cardiac events in persons under 50 years can be attributed to
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amplification of the arterial pulse (24,25), which is greatest
in this younger age group and makes brachial pulse pressure
an uncertain index of aortic pulse pressure.
In the accompanying article by Hundley et al. (7) aortic
distensibility was measured from aortic pulsatile expansion
(using magnetic resonance imaging [MRI]) and brachial
pulse pressure (with a cuff sphygmomanometer). No ac-
count was taken of pressure-wave amplification between the
aorta and brachial artery. For distensibility or like indices to
be measured accurately, pressure and diameter change
should be measured at the same site. This is a fault in the
study, though not a fatal flaw, as pulsatile expansion was
significantly diminished in the diastolic heart failure group
compared to age-matched controls. Individuals wishing to
extend this work are advised to consider this issue carefully
especially when, as in the heart failure patients described
here, factors such as high heart rate and brisk LV ejection
might amplify the brachial pressure pulse with respect to the
aortic pressure pulse (25). Measurement of pulse-wave
velocity by MRI or simpler noninvasive methods would
have been a helpful complement. Another methodologic
anomaly was that arterial systolic and pulse pressures in the
older normal cohort, 124 and 52 mm Hg, respectively, were
considerably less than in the Framingham and the National
Health And Nutrition Examination Survey population at a
similar age, and no different from the younger group.
Several questions follow from the work of Hundley et al.
(7). These include:
1. How does aortic stiffness cause diastolic heart failure?
2. How can aortic stiffening be identified?
3. How can diastolic heart failure be separated from systolic
heart failure?
4. What is the most appropriate treatment of diastolic LV
dysfunction and of diastolic failure?
The first question is readily answered. Aortic stiffening
increases aortic pulse-wave velocity so that wave reflection
returns earlier, augmenting the aortic pressure in systole and
causing relative reduction of aortic pressure throughout diastole
(13,24,25). Effects are of increased aortic and LV systolic
pressure with increased myocardial oxygen demands and LV
hypertrophy, and decreased aortic pressure throughout diastole
with compromised coronary perfusion. Coronary perfusion is
further impaired in LV hypertrophy when ejection duration
also increases and the diastolic period is compromised (26). All
these factors—increased systolic LV pressure, LV hypertrophy
and myocardial ischemia—delay myocardial relaxation and
lead to diastolic heart failure.
Aortic stiffening can readily be identified from the arterial
pulse (11,13,14,25). Early return of wave reflection causes
exaggeration of the second systolic peak—a feature of the
“senile” pulse, which was recognized by Marey (27) in 1860,
and Mahomed in 1872 (28) and was used in the 19th
century to decline applicants for life insurance (29) as well as
in routine clinical practice (11,13). Measurement of aortic
pulse-wave velocity can be accomplished readily (9,10,24,25)
and is particularly useful when systolic heart failure or
change in heart rate alters LV ejection period, and so
complicates interpretation of the arterial pulse (25).
Diastolic dysfunction typically is characterized by delayed
LV relaxation, but there is prolongation of mechanical
systole as well, such that ejection duration is usually in-
creased (25,30). This may provide a practical measure to
identify predominantly diastolic heart failure and separate
this from systolic heart failure because in the latter, ejection
duration typically is decreased (25,31).
If diastolic LV dysfunction is caused by early return of
wave reflection, either directly by raising late systolic pres-
sure or indirectly by causing LV hypertrophy and ischemia,
then it should be relieved by reducing or delaying wave
reflection. This is achieved with angiotensin-converting
enzyme inhibitors, calcium channel antagonists, A2 antag-
onists and nitrates (24,25). These drugs are effective in the
management of diastolic heart failure, especially when
combined with measures or drugs (beta-blockers), which
reduce heart rate and so preserve diastolic relaxation period.
In a recent study (32) verapamil was shown to be particularly
effective in reducing indices of arterial stiffness (carotid
augmentation and aortic pulse-wave velocity), for improving
ventricular/vascular interaction and for increasing capacity
for exercise in older persons with diastolic LV dysfunction.
It is quite likely that agents with similar properties (33) will
be shown to have similar beneficial effects.
The study by Hundley et al. (7) in this issue of the Journal
and other recent articles turn the clock back to the begin-
ning of the 20th century, to Osler’s (14) and Mackenzie’s
(13) interest in arteriosclerosis and its subtle effects on
cardiac function as well as a cause of heart failure. Mack-
enzie (13) related arteriosclerosis to declining physical
performance even at the age of 30, when “running after
trains is not to be done in comfort, and the ascent of hills is
undertaken with more deliberation. All this proceeds pari
passu with diminished resiliency of the arterial wall” (13).
Diastolic heart failure appears to result from the culmi-
nation of stresses on the arteries and heart, and to be the end
result of a process of gradual aortic stiffening, gradual
decline in exercise performance, progressive detuning of
vascular/ventricular interaction, progressive increase in LV
myocyte size, with “pathological” hypertrophy and a situa-
tion that evolutionary forces never had to face when the
human life span was just 20 to 30 years. The subject of
diastolic heart failure is fascinating, and for many reasons; it
takes one back in one dimension to medicine of a past age,
and in another to the links among competitive athletic
prowess, aging and development of frank disease.
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